52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study
Published
Conference Paper
Full Text
Duke Authors
Cited Authors
- Hahn, S; Pena, L; Day, JW; Gambello, M; Gibson, JB; Hillman, R; Kronn, D; Stockton, D; Leslie, N; Tanpaiboon, P; Wang, R; Haack, KA; Sparks, S; Zhao, Y; Kishnani, PS
Published Date
- February 2016
Published In
Volume / Issue
- 117 / 2
Start / End Page
- S54 - S54
Published By
International Standard Serial Number (ISSN)
- 1096-7192
Digital Object Identifier (DOI)
- 10.1016/j.ymgme.2015.12.281